Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options DOI Creative Commons
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1317 - 1317

Published: Nov. 25, 2024

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly affecting young infants, older adults, and individuals with comorbidities. Methods: This document, developed as consensus by an international group experts affiliated the World Association Infectious Diseases Immunological Disorders (WAidid), focuses on recent advancements in RSV prevention, highlighting introduction monoclonal antibodies (mAbs) vaccines. Results: Historically, treatment options were limited to supportive care antibody palivizumab, which required multiple doses. Recent innovations have led development long-acting mAbs, such nirsevimab, provide season-long protection single dose. Nirsevimab has shown high efficacy preventing severe RSV-related lower tract infections (LRTIs) reducing hospitalizations ICU admissions. Additionally, new vaccines, RSVpreF RSVpreF3, target adults demonstrated significant LRTIs clinical trials. Maternal vaccination strategies also show promise providing passive immunity newborns, protecting them during most vulnerable early months life. document further discusses global burden RSV, its economic impact, challenges implementing these preventative different healthcare settings. Conclusions: The evidence supports integration both active (vaccines) immunization approaches effective tools mitigate public health impact RSV. combined use interventions could substantially reduce morbidity mortality across various age groups populations, emphasizing importance widespread efforts.

Language: Английский

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies DOI
Natalie I Mazur, Mauricio T. Caballero, Marta C. Nunes

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10458), P. 1143 - 1156

Published: Sept. 1, 2024

Language: Английский

Citations

17
Early-life respiratory syncytial virus disease and long-term respiratory health DOI
Heather J. Zar, Ferdinand Cacho,

Tahira Kootbodien

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

14
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children DOI
Clint Pecenka, Erin Sparrow, Daniel R. Feikin

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10458), P. 1157 - 1170

Published: Sept. 1, 2024

Language: Английский

Citations

12
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine DOI Creative Commons
Alexander Domnich, Andrea Orsi, Piero Luigi Lai

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 67 - 67

Published: Jan. 3, 2025

Background and Objectives: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of first vaccine-takers can pave way a successful vaccination campaign. The objective this study was to explore sociodemographic clinical Italian users an adjuvanted RSV vaccine their attitudes towards vaccination. Materials Methods: This cross-sectional conducted in 2024 Liguria (Italy). Individuals aged ≥60 years with no contraindications RSVPreF3 OA were eligible. Following vaccination, subjects filled questionnaire, which comprised items on characteristics, trust indicator (VTI). Results: A total 453 vaccinees completed survey. Their mean age 74.9 ± 8.0 years, 50.6% males. Nine ten (89.2%) individuals had ≥1 co-morbidity, cardiovascular conditions (70.4%), diseases (27.6%) diabetes (18.5%) most common. Uptake routine high: 91.2% 98.7% received 2023/2024 season influenza ≥2 COVID-19 vaccines, respectively. common reasons current general practitioner advice (43.9%), followed by willingness be protected against (20.8%) feelings being at risk (16.6%) RSV. average VTI score 91.5%, suggesting high vaccines. More positive observed (p < 0.01) among who more doses, whose or good health feeling Conclusions: novel represented high-risk comparatively prevalence co-morbidities, uptake seasonal immunization.

Language: Английский

Citations

1
Vaccination in Chronic Obstructive Pulmonary Disease DOI Creative Commons
Wang Chun Kwok, Joyce Wong,

A Cheung

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 218 - 218

Published: Feb. 22, 2025

Chronic obstructive pulmonary disease (COPD) is often exacerbated by various viruses and bacteria, leading to acute episodes of worsening respiratory symptoms, which contribute significantly the morbidity mortality associated with COPD. Consequently, vaccination against these pathogens recommended numerous guidelines safeguard COPD patients from adverse health outcomes. The Global Initiative for Obstructive Lung Disease (GOLD) recommendation advocates influenza, Streptococcus pneumoniae, syncytial virus (RSV), severe syndrome coronavirus (SARS-CoV2), pertussis, varicella zoster. This review article will examine current strategies adult discuss clinical benefits vaccines.

Language: Английский

Citations

0
Autophagy and Respiratory Viruses: Mechanisms, Viral Exploitation, and Therapeutic Insights DOI Creative Commons
Farnaz Aligolighasemabadi,

Estera Bakinowska,

Kajetan Kiełbowski

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(6), P. 418 - 418

Published: March 12, 2025

Respiratory viruses, such as influenza virus, rhinovirus, coronavirus, and respiratory syncytial virus (RSV), continue to impose a heavy global health burden. Despite existing vaccination programs, these infections remain leading causes of morbidity mortality, especially among vulnerable populations like children, older adults, immunocompromised individuals. However, the current therapeutic options for viral are often limited supportive care, underscoring need novel treatment strategies. Autophagy, particularly macroautophagy, has emerged fundamental cellular process in host response infections. This not only supports homeostasis by degrading damaged organelles pathogens but also enables xenophagy, which selectively targets particles degradation enhances defense. viruses have evolved mechanisms manipulate autophagy pathways, using them evade immune detection promote replication. review examines dual role manipulation defense, focusing on complex interplay between autophagy-related pathways. By elucidating mechanisms, we aim highlight potential targeting enhance antiviral responses, offering promising directions development effective treatments against

Language: Английский

Citations

0
Burden and characteristics of Respiratory Syncytial Virus-associated respiratory tract infections in adult patients in the winter season 2023/2024 at the conservative emergency department of the university hospital in Dresden DOI Creative Commons

J Ronczka,

Simone von Bonin,

Alexa Laubner

et al.

Virology Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: March 17, 2025

Abstract Introduction The burden of Respiratory Syncytial Virus (RSV) associated adult emergency department visits in comparison to other respiratory viruses like Influenza and SARS-CoV-2 remains less studied. Methods We performed a prospective observational study describe prevalence, severity risk factors RSV infection, proven by polymerase chain reaction from nasopharyngeal or pharyngeal swabs, consecutive patients presenting the ward University Hospital Dresden with working diagnosis acute tract infection during winter season between October 1st 2023 April 15th 2024. Results 1764 adults (56.3% male) 18 101 years old (median age 69 years) were included analysis. 477 (27.1%) tested positive for viral infection; 284 (16.2%) 79 years), 147 (8.4%) A B 56 38 (2.2%) years). In 8 (0.5%) co-infection two was detected. cohort any oxygen support significantly higher (63.2%) compared (34.0%, p < 0.001) (41.5%, = 0.012) cohorts. In-hospital mortality considerable especially 7.9% (2.7%, 0.138) (5.6%, 0.580). Conclusion frequent 2023/24 Influenza, but needed level support. Also, in-hospital considerable, making RSV-infections relevant pathogen an department.

Language: Английский

Citations

0
Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity DOI Creative Commons

Hadeel Alnajran,

Maaweya Awadalla, Fahad M. Aldakheel

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 28, 2025

Attempts to develop an hRSV vaccine have faced safety and efficacy challenges, with only three FDA-approved vaccines (Moderna's Mresvia, Pfizer's Abrysvo, GSK's Arexvy) available. These are limited individuals over 60 years, require boosters, reduce disease severity without clearing the infection. Therefore, we employed a reverse vaccinology approach in this study identify most promising antigenic epitopes capable of eliciting robust protective immune response. This computational techniques design novel multi-epitope targeting hRSV. Using bioinformatics tools, candidate were identified from conserved viral proteins (F G glycoproteins), assessing their immunogenicity, antigenicity, allergenicity. Key tools included ExPASy, ProtParam, VaxiJen v2.0, AllergenFP v1.0, AllerTOP NetCTL v1.2, IEDB, Toxin-Pred. The construct was assessed for stability toxicity through silico analyses. We then characterized its kinetic properties, evaluated structural integrity, analyzed interactions Toll-like receptors (TLRs) using molecular docking, modeling, refinement AlphaFold3 ClusPro. designed constructs showed strong antigenicity (0.5996 F-based 0.6048 G-based vaccine), non-allergenicity, (instability index <40). Among these, amino acids extracellular domain construct. Molecular docking dynamics simulations indicated binding TLR1 TLR4 minimal RMSF fluctuations, which ensured stability. Strong humoral cellular responses suggested by simulation demonstrating activation, high levels IgG, IgM, IL-2, IFN-γ. physical chemical analyses revealed that majority F located presence signal peptide cleavage sites both glycoprotein components further facilitates antigen presentation system. presents peptide-based against can effectively engage system, showing immunogenicity antigenicity. Future vitro vivo studies essential evaluate ability stimulate cell-mediated assess profile.

Language: Английский

Citations

0
Analyzing Differences in Viral Dynamics Between Vaccinated and Unvaccinated RSV Patients DOI Creative Commons

Atika Suri,

SAHAJ SATANI, Hana M. Dobrovolny

et al.

Epidemiologia, Journal Year: 2025, Volume and Issue: 6(2), P. 16 - 16

Published: April 1, 2025

Background: Respiratory syncytial virus (RSV) is a common respiratory that can cause serious illness in infants and the elderly. Vaccines for RSV have recently been introduced shown to reduce severity of disease. However, there has limited examination how viral dynamics differ between vaccinated unvaccinated individuals. Methods: Here, we use data from MVA-BN-RSV Phase II vaccine study quantify dynamical differences patients challenged with RSV. We an ordinary differential equation model within host fit load data. Results: find statistically significant clearance rate basic reproduction number. also experience higher response variance than placebo group. Conclusions: While number are promising, high variability could leave many without adequate protection.

Language: Английский

Citations

0
Choice overload for RSV prevention—how to form your opinion DOI
Natasha Halasa,

Louis Bont

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

1